Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onartuzumab + mFOLFOX6 in HER2-negative gastroesophageal cancer
NCT01590719Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2012
- Primary completion
- Oct 2014
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of onartuzumab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Jul 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01590719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590719.